Full Press Release Details
REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November:
Guggenheim Securities Healthcare Innovation ConferencePresentation Date:Tuesday, November 11, 2025 at 9:00 AM ETPresentation Format:Fireside ChatWebcast:Here
Stifel 2025 Healthcare ConferencePresentation Date:Wednesday, November 12, 2025 at 8:40 AM ETPresentation Format:Fireside ChatWebcast:Here
Jefferies London Healthcare ConferencePresentation Date:Tuesday, November 18, 2025 at 5:00 PM GMTPresentation Format:PresentationWebcast:Here
Replays of the events will be available in the Investors section on the Company’s website atwww.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT XR™ (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visitwww.soleno.life.